Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 24, 2022 (Event Date: February 25, 2022)
Context: The Company entered into a Second Amendment to its Note and Warrant Purchase and Security Agreement (NWPSA) with NH Expansion Credit Fund Holdings LP to secure additional financing and amend existing warrant terms.
Key Financial Metrics and Transaction Details
- New Debt Issuance: $3,000,000 in aggregate original principal amount of incremental secured notes.
- Interest Rate: Prime Rate (or 3.00%, whichever is greater) plus 9.00%, plus 3.00% paid in kind.
- Maturity Date: September 30, 2025.
- Equity Issuance: 20,666,993 shares of Common Stock issued as "Advisor Shares."
- Warrant Amendment: Existing warrant amended to permit exercise for an additional 2.0% of fully-diluted Common Stock; exercise price remains $0.18 per share with a 10-year term.
- Collateral: Notes secured by substantially all assets of the Company and its domestic subsidiary guarantors.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a periodic financial report. The material change is the expansion of the Company's debt facility and the issuance of unregistered equity securities (Advisor Shares and amended warrants) under the amended NWPSA. The filing does not provide comparative financial performance data (revenue, profit, or cash flow) against prior periods.
Guidance, Risks, and Covenants
- Covenants: The agreement includes limitations on indebtedness, liens, dispositions, distributions, investments, and mergers. It also imposes a minimum liquidity covenant.
- Risks: The Company has incurred significant secured debt with a high interest rate structure (Prime + 9% + 3% PIK), which increases financial leverage and interest expense obligations.
- Unusual Items: The issuance of 20.6 million shares as "Advisor Shares" is a non-standard equity issuance tied to the debt amendment.
- Guidance: The filing text does not provide forward-looking financial guidance or management commentary on future operational outlook.
Investor Verification Checklist
- Verify the exact calculation of the "Prime Rate" applicable to the notes and the total effective interest cost including the 3% PIK component.
- Confirm the impact of the 20,666,993 Advisor Shares and the additional 2.0% warrant coverage on existing shareholder dilution.
- Review the full text of the NWPSA (Exhibit 10.1) to understand the specific thresholds for the minimum liquidity covenant and events of default.
- Assess the Company's current liquidity position to ensure compliance with the new minimum liquidity covenant.